Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration

Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration in Early Left Ventricular Dysfunction After Acute Myocardial Infarction And Successful Percutaneous Coronary Intervention

Evaluative pilot study for safety and feasibility with administration of autologous bone bone marrow derived mononuclear cells by endoventricular catheter into the normal border zone fo the ischemic lesion.

Inclusion Criteria:

• LVEF <40%
• PCI at latest 6 hours after infarction
• BMI >20 kg/m² and <30 kg/m²

Exclusion Criteria:

• PCI elder than 14 days
• relevant valvular disease
• left ventricular dysfunction caused by other reasons than ischemic cardiomyopathy
• history of stroke, chronic atrial fibrillation, multivessel disease, thromboembolic event
• scheduled for CABG
• DM Type 1 & extensive hypercholesterinemia
• pacemaker
• systemic disease
• Pregnancy